Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT‐M study

AIMS: To characterize the glycaemic efficacy and safety of initiation of the dipeptidyl peptidase‐4 inhibitor sitagliptin during metformin dose escalation in people with type 2 diabetes (T2D) not at glycated haemoglobin (HbA1c) goal on a sub‐maximal dose of metformin. MATERIALS AND METHODS: Study pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Frias, Juan P., Zimmer, Zachary, Lam, Raymond L.H., Amorin, Guillermo, Ntabadde, Catherine, Iredale, Carol, O'Neill, Edward A., Engel, Samuel S., Kaufman, Keith D., Makimura, Hideo, Crutchlow, Michael F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593795/
https://www.ncbi.nlm.nih.gov/pubmed/30609212
http://dx.doi.org/10.1111/dom.13626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593795/
https://www.ncbi.nlm.nih.gov/pubmed/30609212
http://dx.doi.org/10.1111/dom.13626

Ejemplares similares